natgillin/translations-raw huggingface dataset:
Sodium phosphate, monobasic, monohydrate, Sodium phosphate, dibasic, heptahydrate, Sodium chloride (see section 2 ‘TYSABRI contains sodium'), Polysorbate 80 (E433) 
Druge sestavine so: natrijev dihidrogenfosfat monohidrat natrijev hidrogenfosfat heptahidrat natrijev klorid (glejte poglavje 2 ‘Zdravilo TYSABRI vsebuje natrij') polisorbat 80 (E433) voda za injekcije
Each vial contains 2.3 mmol (or 52 mg) sodium. 
Ena viala vsebuje 2,3 mmol (ali 52 mg) natrija.
Your doctor may test your blood to check if you have antibodies to the JC virus before you start treatment with TYSABRI. 
Vaš zdravnik vam bo morda pred začetkom zdravljenja z zdravilom TYSABRI dal pregledati kri, da ugotovi morebitno prisotnost protiteles proti virusu JC.
If you miss your usual dose of TYSABRI, arrange with your doctor to receive it as soon as you can. You can then continue to receive your dose of TYSABRI every 4 weeks. 
Če ste izpustili običajni odmerek zdravila TYSABRI, se z zdravnikom dogovorite, da ga boste prejeli čim prej.
What TYSABRI looks like and contents of the pack TYSABRI is a clear, colourless to slightly cloudy liquid. 
Zdravilo TYSABRI je bistra, brezbarvna ali rahlo motna tekočina.
TYSABRI will be given to you by a doctor experienced in the treatment of MS. 
Kako uporabljati zdravilo TYSABRI Zdravilo TYSABRI da zdravnik z izkušnjami v zdravljenju MS.
A condition called JCV GCN (JC virus granule cell neuronopathy) is also caused by JC virus and has occurred in some patients who have been given TYSABRI. 
Virus JC lahko povzroči tudi bolezen, imenovano JCV GCN (JCV nevropatija zrnatih celic), o kateri so poročali pri nekaterih bolnikih, zdravljenih z zdravilom TYSABRI.
The reactions are reported as MedDRA preferred terms under the MedDRA primary system organ class. 
Neželeni učinki so navedeni z izrazi, ki jih priporoča MedDRA in glede na MedDRA organske sisteme.
Some patients with a past medical history of an abnormal liver test have experienced an exacerbation of abnormal liver test while on TYSABRI. 
Pri nekaterih bolnikih, katerih testi so v preteklosti pokazali nepravilnosti v delovanju jeter, so se vrednosti med jemanjem zdravila TYSABRI še poslabšale.
After dilution (see section 6.6), the infusion is to be administered over approximately 1 hour and patients are to be observed during the infusion and for 1 hour after the completion of the infusion for signs and symptoms of hypersensitivity reactions. 
Bolnika se v času infundiranja in 1 uro po končanem infundiranju opazuje za znake in simptome preobčutljivostnih reakcij.
Breast-feeding should be discontinued during treatment with TYSABRI. 
Med zdravljenjem z zdravilom TYSABRI je treba prenehati z dojenjem.
This is because patients who received one or two doses of TYSABRI and then had a gap in treatment of three months or more, were more likely to have an allergic reaction when resuming treatment. 
TYSABRI, nato pa prekinili zdravljenje za tri mesece ali več, pogosteje pojavile alergije, ko so ponovno pričeli z zdravljenjem.
In addition to this leaflet you will be given a Patient Alert Card, which contains important safety information that you need to know before you are given TYSABRI (pronounced tie-SA-bree) and during treatment with TYSABRI. 
Poleg teh navodil boste prejeli tudi kartico s posebnimi opozorili za bolnika, ki vsebuje pomembne informacije v zvezi z varnostjo, za katere morate vedeti, preden začnete z zdravljenjem z zdravilom
Each vial of TYSABRI contains 2.3 mmol (or 52 mg) of sodium. 
Ena viala zdravila TYSABRI vsebuje 2,3 mmol (ali 52 mg) natrija.
• Feeling sick (nausea) 
• huda alergija (preobčutljivost)
After the infusion is complete, flush the intravenous line with sodium chloride 9 mg/ml (0.9%) solution for injection. 
Po končanem infundiranju sperite intravensko linijo z natrijevim kloridom 9 mg/ml (0,9 %) raztopino za injiciranje.
In 10% of patients antibodies against natalizumab were detected in 2-year controlled clinical trials in MS patients. 
V dveletnih kontroliranih kliničnih preskušanjih pri bolnikih z MS so bila pri 10 % bolnikov odkrita protitelesa proti natalizumabu.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION TYSABRI 300 mg concentrate for solution for infusion natalizumab 
IME ZDRAVILA IN POT(I) UPORABE TYSABRI 300 mg koncentrat za raztopino za infundiranje natalizumab intravenska uporaba
Continuous dosing with TYSABRI is important, especially during the first few months of treatment. 
Neprekinjeno odmerjanje zdravila TYSABRI je pomembno še posebej prvih nekaj mesecev zdravljenja, zato ker so se pri bolnikih, ki so prejeli enega ali dva odmerka zdravila
Tell your doctor immediately if you have, or think you have, any sort of infection (see side effects). 
Če imate ali mislite, da imate kakršno koli vrsto okužbe (glejte neželene učinke), o tem takoj obvestite zdravnika.
• Prescriber name, signature and date 
• ime, podpis in datum zdravnika, ki predpisuje zdravilo
What TYSABRI contains 
Kaj vsebuje zdravilo TYSABRI
Platelet counts were also reduced in offspring born to mothers treated with natalizumab until parturition, however there was no evidence of anaemia in these offspring. 
Potomci, rojeni materam, tretiranih z natalizumabom do skotitve, so imeli zmanjšano število trombocitov, vendar niso kazali znakov anemije.
In cases of significant liver injury TYSABRI should be discontinued. 
V primeru hujših okvar jeter je treba zdravljenje z zdravilom TYSABRI prekiniti.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of concentrate contains 20 mg of natalizumab. 
En ml koncentrata vsebuje 20 mg natalizumaba.
MedDRA System Organ Class Adverse reaction 
Organski sistem po MedDRA Neželeni učinek
Discontinue administration of TYSABRI and initiate appropriate therapy at the first symptoms or signs of hypersensitivity. 
Ob pojavu prvih simptomov ali znakov preobčutljivosti prenehajte z dajanjem zdravila TYSABRI in uvedite ustrezno zdravljenje.
• You may not be able to use TYSABRI if you are currently receiving or have previously received medicines that affect your immune system, e.g. mitoxantrone or cyclophosphamide. 
• Če trenutno jemljete ali ste predhodno prejemali zdravila, ki vplivajo na imunski sistem, npr.
Relapse free 
(ODGOVORNI) ZA SPROŠČANJE SERIJ
• After the infusion is complete, flush the intravenous line with sodium chloride 9 mg/ml (0.9%) solution for injection. 
• Po končanem infundiranju sperite intravensko linijo z natrijevim kloridom 9 mg/ml (0,9 %)
• Being sick (vomiting) 
• srbeč izpuščaj (koprivnica)
Randomised 
Preizkušanci
Dilute before infusion. 
Pred infundiranjem razredčite.
• Add the 15 ml concentrate for solution for infusion to 100 ml sodium chloride 9 mg/ml (0.9%) solution for injection. 
• 15 ml koncentrata za raztopino za infundiranje dodajte 100 ml natrijevega klorida 9 mg/ml
• Urinary tract infection 
• okužbe sečil
Rare side effects that may affect up to 1 in 1,000 people: 
• progresivna multifokalna levkoencefalopatija (PML) Redki neželeni učinki, ki lahko prizadenejo največ 1 od 1.000 bolnikov:
In patients considered at high risk treatment with TYSABRI should only be continued if the benefits outweigh the risks. 
Pri bolnikih, pri katerih je tveganje veliko, se sme zdravljenje z zdravilom TYSABRI nadaljevati le,
In 2-year controlled clinical trials in MS patients, an infusion-related event was defined as an adverse event occurring during the infusion or within 1 hour of the completion of the infusion. 
opredelili kot neželen dogodek, ki se pojavi med infundiranjem ali v eni uri od zaključenega infundiranja.
In 2-year controlled clinical trials in MS patients TYSABRI treatment was associated with increases in circulating lymphocytes, monocytes, eosinophils, basophils and nucleated red blood cells. 
TYSABRI povezano s povišanim obtokom limfocitov, monocitov, eozinofilcev, bazofilcev in eritrocitov z jedrom.
MS and inhibits further recruitment of immune cells into inflamed tissue, thus reducing the formation or enlargement of MS lesions. 
Blokada molekulske interakcije α4β1 s tarčnimi strukturami zmanjšuje vnetno aktivnost v možganih pri MS in preprečuje nadaljnje vključevanje imunskih celic v vnetno tkivo, kar zmanjšuje nastajanje ali povečevanje lezij zaradi MS.
Given that efficacy may be reduced or the incidence of hypersensitivity or infusion-related reactions may be increased in a patient with persistent antibodies, treatment should be discontinued in patients who develop persistent antibodies. 
Ker se lahko pri bolnikih z obstojnimi protitelesi učinkovitost zmanjša ali poveča pojavnost preobčutljivosti ali z infuzijo povezanih reakcij,
How to store TYSABRI 
Shranjevanje zdravila TYSABRI
• Information on PML and IRIS including the risk of developing PML during TYSABRI treatment stratified by prior treatment with immunosuppressants and JC virus infection. 
• informacije o PML in IRIS, vključno s tveganjem za razvoj PML med zdravljenjem z zdravilom
TYSABRI therapy and without prior history of immunosuppressant therapy. 
TYSABRI, opredeljeno glede na predhodno zdravljenje z imunosupresivi in okužbo z virusom JC
• Dizziness 
• bruhanje
• TYSABRI must be diluted before it is given to you. 
• Pred uporabo je treba zdravilo TYSABRI razredčiti.
Warnings and precautions Talk to your doctor before using TYSABRI. 
Pred začetkom uporabe zdravila TYSABRI se posvetujte s svojim zdravnikom.
− Weight loss 
Razredčena raztopina
Stopping TYSABRI therapy 
Prenehanje zdravljenja z zdravilom TYSABRI
• Difficulty breathing 
Težave z jetri
This includes: 
ali se je kaj spremenilo, če:
Do not use if it is discoloured or if foreign particles are seen. 
Obarvane raztopine ali raztopine, v kateri so delci, ne smete uporabiti.
In 2-year controlled clinical trials in MS patients, the rate of infection was approximately 1.5 per patient-year in both natalizumab- and placebo-treated patients. 
Okužbe, vključno s PML in oportunističnimi okužbami V dveletnih kontroliranih kliničnih preskušanjih pri bolnikih z MS je bila stopnja okužbe približno 1,5
• Severe allergy (hypersensitivity) • Progressive multifocal leukoencephalopathy (PML) 
Bolezni živčevja glavobol pogosti omotica pogosti progresivna multifokalna levkoencefalopatija (PML)
One year endpoint 
Opazovani dogodek - eno leto
Rare, serious cases of anaemia and haemolytic anaemia have been reported in patients treated with TYSABRI in post-marketing observational studies. 
V opazovalnih študijah po prihodu zdravila na trg so pri bolnikih, zdravljenih z zdravilom Tysabri,
Urinary tract infection 
raztopino za injiciranje.
Vomiting 
Imunogenost
• Inspect the TYSABRI vial for particles prior to dilution and administration. 
• Pred razredčitvijo in dajanjem zdravila TYSABRI preverite, ali so v viali delci.
EXP 
CHMP.
More frequent MRIs (e.g. on a 3 to 6 monthly basis) using an abbreviated protocol should be considered for patients at higher risk of PML. 
Za bolnike, pri katerih je tveganje za PML večje, je treba razmisliti o pogostejšem MRS (npr. vsake 3 do
EDSS-baseline, median (range) 
mediana (razpon)
Inspect the TYSABRI vial for particles prior to dilution and administration. 
Pred razredčitvijo in dajanjem zdravila TYSABRI preverite, ali so v viali delci.
In placebo-controlled trials in 1,617 MS patients treated with natalizumab for up to 2 years (placebo: 1,135), adverse events leading to discontinuation of therapy occurred in 5.8% of patients treated with natalizumab (placebo: 4.8%). 
2 leti (placebo: 1.135) je prišlo do neželenih učinkov, zaradi katerih je bilo zdravljenje prekinjeno, pri
Mean number of Gd-enhancing lesions 
Povprečno število lezij, vidnih z gadolinijem
− Listlessness 
• slabost
− Prolonged dizziness 
Brez recidiva
The European Commission granted a marketing authorisation valid throughout the European Union for Optimark on 23 July 2007. 
Evropska komisija je dovoljenje za promet z zdravilom Optimark, veljavno po vsej Evropski uniji, izdala 23. julija 2007.
The recommended dose is 0.2 ml per kilogram body weight. 
Priporočeni odmerek je 0,2 ml na kilogram telesne mase.
Other information about Optimark: 
Druge informacije o zdravilu Optimark:
What measures are being taken to ensure the safe and effective use of Optimark? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Optimark?
In addition, the company will provide annual reviews of cases of NSF and conduct a study on the accumulation of gadolinium in the bone. 
Poleg tega bo zagotovila letna poročila primerov NSF in izvedla študijo o kopičenju gadolinija v kosteh.
The full EPAR for Optimark can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Optimark je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Each scan's clarity was scored on a four-point scale. 
Jasnost vsake slike je bila ocenjena s štiristopenjsko lestvico.
The company that markets Optimark will ensure that all healthcare professionals who are expected to use this medicine are informed that it should not be used in children below 2 years as the effect of the medicine in this age group, such as its effect on immature kidneys, has not been studied. 
Družba, ki trži zdravilo Optimark, bo poskrbela, da bodo vsi zdravstveni delavci, ki naj bi predpisovali to zdravilo, obveščeni, da se ne sme uporabljati pri otrocih, mlajših od dveh let, saj učinek zdravila pri tej starostni skupini, kot na primer učinek zdravila na nezrele ledvice, ni bil raziskan.
The scans were analysed by three radiologists (doctors specialised in carrying out and interpreting scans of the body). 
Slike so analizirali trije radiologi (zdravniki, specializirani za slikanje telesa in tolmačenje slik).
In Optimark, the gadolinium is attached to another chemical so that the metal is not released in the body but stays ‘trapped' until it is eliminated from the body in the urine. 
V zdravilu Optimark je gadolinij vezan na drugo kemijsko spojino, tako da se kovina v telesu ne sprosti, ampak ostane „ujeta“, dokler se z urinom ne izloči iz telesa.
This is a summary of the European public assessment report (EPAR) for Optimark. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Optimark.
As a result of this interaction, the water molecules give a stronger signal, and this helps to obtain a brighter picture. 
Zaradi tega vpliva začnejo vodne molekule oddajati močnejši signal, kar omogoča jasnejšo sliko.
It is given as an injection into a vein, usually a vein in an arm. 
Daje se z injekcijo v veno, po navadi v veno roke.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Optimark have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki za varno in učinkovito uporabo zdravila Optimark, so prav tako vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
The CHMP decided that Optimark's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Optimark večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
What benefit has Optimark shown during the studies? 
Kakšne koristi je zdravilo Optimark izkazalo med študijami?
Patients who have moderate problems with their kidneys should only receive Optimark if their doctor has carefully balanced the benefits and risks of using it. 
Bolniki z zmernimi težavami z ledvicami lahko zdravilo Optimark prejmejo le, če je zdravnik pazljivo pretehtal koristi in tveganja njegove uporabe.
For more information about treatment with Optimark, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Optimark preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Optimark is for diagnostic use. 
Zdravilo Optimark je namenjeno diagnostični uporabi.
A repeated dose is not recommended in children, in patients with kidney problems or in elderly patients. 
Ponavljajoč odmerek ni priporočljiv za otroke, bolnike z obolenji ledvic in starejše bolnike.
It is used in adults and in children from two years of age who are undergoing magnetic resonance imaging (MRI), a type of scan where images of the internal organs are taken. 
Uporablja se pri odraslih in otrocih, starejših od dveh let, pri katerih se izvaja magnetnoresonančno slikanje (MRS), tj. vrsta slikanja notranjih organov.
When looking at certain abnormalities in the brain, Optimark may need to be used at a higher dose, or the dose may need to be repeated. 
Pri proučevanju določenih nepravilnosti v možganih bo morda treba uporabiti večji odmerek zdravila Optimark ali pa odmerek ponoviti.
Optimark has been studied in four main studies involving a total of 804 patients who had or were thought to have abnormalities in the brain or spine (two studies in 401 patients) or in the liver (two studies in 403 patients). 
Zdravilo Optimark so proučevali v štirih glavnih študijah s skupno 804 bolniki z znanimi ali domnevnimi nepravilnostmi v možganih ali hrbtenjači (dve študiji s skupno 401 bolnikom) ali jetrih (dve študiji s skupno 403 bolniki).
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Optimark. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Optimark allows images to be taken for up to an hour after it has been injected, although the best time to take a scan depends on the location and type of abnormality that is being examined. 
Zdravilo Optimark omogoča slikanje največ eno uro po injiciranju, čeprav je najboljši čas za slikanje odvisen od predela in vrste obravnavane nepravilnosti.
It is available in prefilled syringes and in vials. 
Na voljo je v napolnjenih injekcijskih brizgah in vialah.
Optimark must not be used in people who are hypersensitive (allergic) to gadoversetamide, any of the other ingredients or other medicines containing gadolinium. 
Zdravila Optimark ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) gadoversetamid, katero koli drugo sestavino zdravila ali druga zdravila, ki vsebuje gadolinij.
MRI is an imaging method that relies on the tiny magnetic fields produced by water molecules in the body. 
Magnetnoresonančno slikanje je metoda slikanja in temelji na majhnih magnetnih poljih, ki jih ustvarjajo vodne molekule v telesu.
Once injected, gadolinium interacts with the water molecules. 
Gadolinij po injiciranju vpliva na vodne molekule.
In the studies of liver abnormalities, both medicines increased the score by an average of 0.38 points from a baseline of 1.82 points. 
V študijah nepravilnosti v jetrih se je rezultat pri obeh zdravilih izboljšal za povprečno 0,38 točke glede na izhodiščno vrednost 1,82 točke.
Optimark is used to obtain a clearer scan in patients who have or are thought to have abnormalities in the brain, spine or liver. 
Zdravilo Optimark se uporablja za doseganje jasnejše slike pri bolnikih z znanimi ali domnevnimi nepravilnostmi v možganih, hrbtenici ali jetrih.
The main measure of effectiveness was the difference in the ability to see the abnormalities on MRI scans taken with and without the contrast agent. 
Glavno merilo učinkovitosti je bila razlika v razločljivosti nepravilnosti na magnetnoresonančnih slikah, posnetih s kontrastnim sredstvom oziroma brez njega.
The radiologists did not know what treatment the patient had received beforehand, to make sure that the studies' findings were as accurate as possible. 
Da bi bili izsledki študije čim bolj natančni, radiologi niso vedeli, kakšno zdravljenje je bolnik pred tem prejel.
What is the risk associated with Optimark? 
Kakšna tveganja so povezana z zdravilom Optimark?
Optimark should only be given by a doctor who has experience in using MRI. 
Zdravilo Optimark sme dajati samo zdravnik, ki ima izkušnje z uporabo magnetnoresonančnega slikanja.
In all of the studies, the effects of Optimark were compared with those of gadopentetate dimeglumine (another contrast agent containing gadolinium). 
Učinke zdravila Optimark so v vseh študijah primerjali z učinki gadopentetat dimeglumina (drugega kontrastnega sredstva, ki vsebuje gadolinij).
NSF causes thickening of the skin and connective tissues. 
Nefrogena sistemska fibroza povzroča odebelitev kože in veznih tkiv.
These patients should receive no more than one dose of Optimark during each MRI scan, and there should be a gap of at least a week between each Optimark injection. 
Med vsakim magnetnoresonančnim slikanjem lahko ti bolniki prejmejo samo en odmerek zdravila Optimark, med dvema injiciranjema pa mora preteči najmanj en teden.
In the two studies of brain and spine abnormalities taken together, scans taken with Optimark had a score increase of 0.63 points on average from a ‘baseline' of 1.58 points without Optimark. 
V dveh študijah nepravilnosti v možganih in hrbtenici je bilo na slikah, posnetih ob jemanju zdravila Optimark, doseženo povprečno izboljšanje rezultata za 0,63 točke (izhodiščna vrednost brez zdravila Optimark je bila 1,58 točke).
Why has Optimark been approved? 
Zakaj je bilo zdravilo Optimark odobreno?
This compared with an increase of 0.66 points with the comparator contrast agent, from a baseline of 1.60 points. 
Pri primerjalnem kontrastnem sredstvu je bilo opaženo izboljšanje za 0,66 točke, pri čemer je bila izhodiščna vrednost 1,60 točke.
Optimark is a solution for injection that contains the active substance gadoversetamide. 
Zdravilo Optimark je raztopina za injiciranje, ki vsebuje zdravilno učinkovino gadoversetamid.
The most common side effects with Optimark (seen in between 1 and 10 patients in 100) are headache, dysgeusia (taste disturbances) and feeling hot. For the full list of all side effects reported with Optimark, see the package leaflet. 
Najpogostejši neželeni učinki zdravila Optimark (opaženi pri 1 do 10 bolnikih od 100) so glavobol, disgevzija (motnje okušanja) in občutek vročine.
The active substance in Optimark, gadoversetamide, contains gadolinium, a ‘rare-earth' metal element. 
Zdravilna učinkovina zdravila Optimark, gadoversetamid, vsebuje redko zemeljsko kovino gadolinij.
It must not be used in patients who have severely reduced kidney function, in patients who have had or are about to have a liver transplant, or in babies aged less than four weeks, due to a risk of a condition called nephrogenic systemic fibrosis (NSF). 
Zaradi tveganja za nefrogeno sistemsko fibrozo (NSF) se ne sme uporabljati pri bolnikih s hudo okvaro delovanja ledvic, pri bolnikih, pri katerih so ali bodo presadili jetra, ali pri dojenčkih, mlajših od štirih tednov.
How has Optimark been studied? 
Kako je bilo zdravilo Optimark raziskano?
In all of the studies, Optimark was as effective as the comparator contrast agent in improving the ability to see abnormalities on the scans. 
Zdravilo Optimark je bilo pri izboljšanju razločljivosti nepravilnosti na slikah v vseh študijah enako učinkovito kot primerjalno kontrastno sredstvo.
How does Optimark work? 
Kako zdravilo Optimark deluje?
What is Optimark used for? 
Za kaj se zdravilo Optimark uporablja?
What is Optimark? 
Kaj je zdravilo Optimark?
How is Optimark used? 
Kako se zdravilo Optimark uporablja?
Gadolinium is used as a ‘contrast agent' to help obtain better images with MRI scans. 
Ta se uporablja kot kontrastno sredstvo, ki zagotavlja boljše slike, izdelane z magnetnoresonančnim slikanjem.
Strength Pharmaceutical Form Route of Administration 
Farmacevtska oblika Pot uporabe Stična ovojnina
90 (3 x 30) tablets 
Peroralna uporaba Plastenka (HDPE) 90 (3 x 30) tablet
MA (EU) number Invented name Strength Pharmaceutical form 
Izmišljeno ime Jakost Farmacevtska oblika Pot uporabe
30 tablets 
Peroralna uporaba Plastenka (HDPE) 30 tablet
Route of administration 
Številka (EU) dovoljenja za promet
Take it as soon as you remember. 
Uporabite ga, čim se spomnite.